GenoLogics Announces Availability of Clarity LIMS 3.1
News Aug 07, 2014
GenoLogics Life Sciences Software has announced the availability of Clarity LIMS 3.1. In addition to providing support for HIPAA-covered entities, Clarity LIMS extends its toolset for labs working with patient populations with features that support clinical compliance.
Version 3.1 further supports the needs of these labs with electronic signatures, configurable permissions, and detailed audit trail reporting.
To help labs conduct operations electronically, regulating agencies, such as the FDA, have published standards-21 CFR Part 11 is one-that describe how electronic approvals or signatures should be recorded.
Clarity LIMS is designed to this standard and allows labs to configure electronic signature requirements, without developer intervention, which supports compliance yet speeds implementation. Furthermore, Clarity LIMS prevents processes that are missing required approvals from moving forward.
21 CFR Part 11 also requires that systems restrict functionality to users with appropriate permissions to prevent error, data loss, or tampering. Clarity LIMS meets this requirement with configurable role-based permissions, preventing access where not needed.
Adding to this security is the system’s ability to produce a human readable audit trail that details all system events, who performed the events, and when. A record of the previously recorded data is also kept if the event involved a change to data.
“We are proud to release version 3.1 of Clarity LIMS and further support compliance requirements,” states Michael Ball, CEO of GenoLogics. Ball adds, “These features reiterate our dedication to make next generation sequencing a mainstay in clinical environments.”
Sysmex Partners with Laboratories to Deliver Improved QC ManagementNews
Sysmex America has announced its latest innovation: a way to make quality assurance easier and more risk free than manual quality control processes.READ MORE
BMS, QIAGEN Partner to Develop Gene Expression Profiles for Immuno-OncologyNews
QIAGEN and Bristol-Myers Squibb intend to develop GEPs for several Bristol-Myers Squibb I-O molecules under the initial agreement.READ MORE
Comments | 0 ADD COMMENT
EMBL Course: Introduction to Next Generation Sequencing
Apr 09 - Apr 12, 2018
EMBL Course: RNA Sequencing Library Preparation - How Low Can You Go?
Mar 19 - Mar 23, 2018
EMBL Course: Analysis and Integration of Transcriptome and Proteome Data
Mar 12 - Mar 16, 2018